NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

By Nikita Chaurasia  Date: 2020-08-03

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures among critical patients of COVID-19. According to independent researchers, RLF-100 apparently blocks the multiplication of the SARS coronavirus in human lung cells as well as monocytes.

The first rapid clinical recuperation report was posted by doctors from Houston Methodist Hospital. It described the recovery of a 54-year-old man who contracted COVID-19 while being treated for rejection of a multiple lung transplant and was taken off the ventilator within four days of treatment.

Similar outcomes were observed in more than 15 cases treated under emergency use IND (Investigational New Drug), sources claimed. The FDA extended its access protocols which are available to critically ill patients admitted to the current Phase 2/3 FDA trials

Sources with relevant information cited that critically ill COVID-19 patients witnessed a quick recovery from pneumonitis, as displayed by the findings on their x-ray reports. Moreover, an improvement in the patients’ blood oxygen levels were seen alongside a 50% decrease in test center markers related to COVID-19 inflammation.

Prof. Jonathan Javitt, CEO and Chairman of NeuroRx was reported stating that other antiviral agents have failed to show such fast recuperation from a viral disease and exhibited inhibitions towards the multiplication of the virus. He further said that placebo-controlled trials are being carried out by NeuroRx in order to analyze the observations made during open-label and case-control studies.

For those uninitiated, RF-100 is an antiviral agent that has been developed as a Material Threat Medical Countermeasure.

The FDA has reportedly granted Fast Track designation to this antiviral, which is developed through a joint venture agreement among National Institute of Health and numerous other federal agencies, the medicine is being developed as a Material Threat Medical Countermeasure.

 

Source Credits: https://www.prnewswire.com/news-releases/rlf-100-aviptadil-clinical-trial--showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-301104384.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

U.K. might ease lockdown restrictions following drop in COVID-19 cases

U.K. might ease lockdown restrictions following drop in COVID-19 cases

By Nikita Chaurasia

British Prime Minister Boris Johnson is reportedly planning to further ease lockdown restrictions in the United Kingdom. This announcement comes after Britain witnessed a drop in the daily death toll and case count, primarily due to rapid vaccination...

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

By Nikita Chaurasia

Maruti Suzuki India Limited has reportedly extended its maintenance shutdown from May 9th to May 16th amidst rising COVID-19 cases across the country. However, it is difficult to ascertain whether the intention behind the extended shutdown is to guar...

Amazon sets tougher rules for its delivery service partners’ employees

Amazon sets tougher rules for its delivery service partners’ employees

By Nikita Chaurasia

Amazon is known for closely managing its staff and contractors, and it also seeks to control the employees of the companies in which it works. Reportedly, the company has updated its policies for Amazon’s delivery partners wherein it lays out d...

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

By Nikita Chaurasia

Solid Power Inc., a leading U.S-based producer of solid-state batteries has reportedly secured USD 130 million in the Series B funding round led by renowned car makers namely Ford Motor Company and BMW Group.  These funds will be used to develo...

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

By Nikita Chaurasia

Reportedly, American multinational pharmaceutical firm Pfizer Inc. has extended a helping hand to India in the battle against Covid-19, sending drugs worth USD 70 million to the country. The company is also in discussion with the Indian government to...